Safety of the adjuvanted recombinant zoster vaccine in adults aged 50 years or older. A phase IIIB, non-randomized, multinational, open-label study in previous ZOE-50 and ZOE-70 placebo recipients
Authors:
- ZOSTER-056 Study GroupZGZOSTER-056 Study Group
Open Access
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Safety profile of the adjuvanted recombinant zoster vaccine: Pooled analysis of two large randomised phase 3 trialsVaccine, 2019
- Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster VaccinesMMWR. Morbidity and Mortality Weekly Report, 2018
- Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or OlderNew England Journal of Medicine, 2016
- Efficacy of an Adjuvanted Herpes Zoster Subunit Vaccine in Older AdultsNew England Journal of Medicine, 2015
- Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: A phase II, randomized, controlled studyVaccine, 2014
- The global epidemiology of herpes zosterNeurology, 2013
- Safety and Immunogenicity of an AS01-adjuvanted Varicella-zoster Virus Subunit Candidate Vaccine Against Herpes Zoster in Adults >=50 Years of AgeThe Journal of Infectious Diseases, 2013
- A Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older AdultsNew England Journal of Medicine, 2005